

















































































- (ARID1A/SMARCF1) subunit of mammalian SWI/SNF-related complexes is essential for normal cell cycle arrest. *Cancer Res.* 2005;65(20):9236–44.
147. Jones S, Wang T-L, Shih I-M, Mao T-L, Nakayama K, Roden R, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. *Science.* 2010;330(6001):228–31.
148. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. *N Engl J Med.* 2010;363(16):1532–43.
149. Parsons DW, Li M, Zhang X, Jones S, Leary RJ, Lin JC-H, et al. The genetic landscape of the childhood cancer medulloblastoma. *Science.* 2011;331(6016):435–9.
150. Huang J, Zhao Y-L, Li Y, Fletcher JA, Xiao S. Genomic and functional evidence for an ARID1A tumor suppressor role. *Genes Chromosomes Cancer.* 2007;46(8):745–50.
151. Shen H, Powers N, Saini N, Comstock CES, Sharma A, Weaver K, et al. The SWI/SNF ATPase Brm is a gatekeeper of proliferative control in prostate cancer. *Cancer Res.* 2008;68(24):10154–62.
152. Fukuoka J, Fujii T, Shih JH, Dracheva T, Meerzaman D, Player A, et al. Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer. *Clin Cancer Res.* 2004;10(13):4314–24.
153. Reisman DN, Sciarrotta J, Wang W, Funkhouser WK, Weissman BE. Loss of

- BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis. *Cancer Res.* 2003;63(3):560–6.
154. Medina PP, Romero OA, Kohno T, Montuenga LM, Pio R, Yokota J, et al. Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines. *Hum Mutat.* 2008;29(5):617–22.
155. Medina PP, Carretero J, Fraga MF, Esteller M, Sidransky D, Sanchez-Cespedes M. Genetic and epigenetic screening for gene alterations of the chromatin-remodeling factor, SMARCA4/BRG1, in lung tumors. *Genes Chromosomes Cancer.* 2004;41(2):170–7.
156. Wong AK, Shanahan F, Chen Y, Lian L, Ha P, Hendricks K, et al. BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines. *Cancer Res.* 2000;60(21):6171–7.
157. Rodriguez-Nieto S, Cañada A, Pros E, Pinto AI, Torres-Lanzas J, Lopez-Rios F, et al. Massive parallel DNA pyrosequencing analysis of the tumor suppressor BRG1/SMARCA4 in lung primary tumors. *Hum Mutat.* 2011;32(2):E1999-2017.
158. Schneppenheim R, Frühwald MC, Gesk S, Hasselblatt M, Jeibmann A, Kordes U, et al. Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome. *Am J Hum Genet.* 2010;86(2):279–84.
159. Drost J, Mantovani F, Tocco F, Elkon R, Comel A, Holstege H, et al. BRD7 is a candidate tumour suppressor gene required for p53 function. *Nat Cell Biol.*

2010;12(4):380–9.

160. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. *Proc Natl Acad Sci U S A*. 1971;68(4):820–3.
161. Wilson BG, Roberts CWM. SWI/SNF nucleosome remodellers and cancer. *Nat Rev Cancer*. 2011;11(7):481–92.
162. Josling GA, Selvarajah SA, Petter M, Duffy MF. The role of bromodomain proteins in regulating gene expression. *Genes (Basel)*. 2012;3(2):320–43.
163. Phelan ML, Sif S, Narlikar GJ, Kingston RE. Reconstitution of a core chromatin remodeling complex from SWI/SNF subunits. *Mol Cell*. 1999;3(2):247–53.
164. Zhang Z-K, Davies KP, Allen J, Zhu L, Pestell RG, Zagzag D, et al. Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5. *Mol Cell Biol*. 2002;22(16):5975–88.
165. Taft RJ, Pang KC, Mercer TR, Dinger M, Mattick JS. Non-coding RNAs: regulators of disease: Non-coding RNAs: regulators of disease. *J Pathol*. 2010;220(2):126–39.
166. Zampetaki A, Albrecht A, Steinhofel K. Long non-coding RNA structure and function: Is there a link? *Front Physiol*. 2018;9:1201.
167. Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. *Cell*. 2009;136(4):642–55.

168. Liu Y, Dou M, Song X, Dong Y, Liu S, Liu H, et al. The emerging role of the piRNA/piwi complex in cancer. *Mol Cancer*. 2019;18(1):123.
169. Post C, Clark JP, Sytnikova YA, Chirn G-W, Lau NC. The capacity of target silencing by *Drosophila* PIWI and piRNAs. *RNA*. 2014;20(12):1977–86.
170. Kuramochi-Miyagawa S, Watanabe T, Gotoh K, Totoki Y, Toyoda A, Ikawa M, et al. DNA methylation of retrotransposon genes is regulated by Piwi family members MILI and MIWI2 in murine fetal testes. *Genes Dev*. 2008;22(7):908–17.
171. Zhang H, Ren Y, Xu H, Pang D, Duan C, Liu C. The expression of stem cell protein Piwil2 and piR-932 in breast cancer. *Surg Oncol*. 2013;22(4):217–23.
172. Reeves ME, Firek M, Jliedi A, Amaar YG. Identification and characterization of RASSF1C piRNA target genes in lung cancer cells. *Oncotarget*. 2017;8(21):34268–82.
173. Yao J, Wang YW, Fang BB, Zhang SJ, Cheng BL. piR-651 and its function in 95-D lung cancer cells. *Biomed Rep*. 2016;4(5):546–50.
174. Li D, Luo Y, Gao Y, Yang Y, Wang Y, Xu Y, et al. piR-651 promotes tumor formation in non-small cell lung carcinoma through the upregulation of cyclin D1 and CDK4. *Int J Mol Med*. 2016;38(3):927–36.
175. Cheng J, Guo J-M, Xiao B-X, Miao Y, Jiang Z, Zhou H, et al. piRNA, the new non-coding RNA, is aberrantly expressed in human cancer cells. *Clin Chim Acta*.



2011;412(17-18):1621-5.

176. Martinez VD, Enfield KSS, Rowbotham DA, Lam WL. An atlas of gastric PIWI-interacting RNA transcriptomes and their utility for identifying signatures of gastric cancer recurrence. *Gastric Cancer*. 2016;19(2):660-5.
177. Weng W, Liu N, Toiyama Y, Kusunoki M, Nagasaka T, Fujiwara T, et al. Novel evidence for a PIWI-interacting RNA (piRNA) as an oncogenic mediator of disease progression, and a potential prognostic biomarker in colorectal cancer. *Mol Cancer*. 2018;17(1):16.
178. Chu H, Xia L, Qiu X, Gu D, Zhu L, Jin J, et al. Genetic variants in noncoding PIWI-interacting RNA and colorectal cancer risk: PiRNA SNPs and Colorectal Cancer Risk. *Cancer*. 2015;121(12):2044-52.
179. Yin J, Jiang X-Y, Qi W, Ji C-G, Xie X-L, Zhang D-X, et al. piR-823 contributes to colorectal tumorigenesis by enhancing the transcriptional activity of HSF1. *Cancer Sci*. 2017;108(9):1746-56.
180. Mai D, Ding P, Tan L, Zhang J, Pan Z, Bai R, et al. PIWI-interacting RNA-54265 is oncogenic and a potential therapeutic target in colorectal adenocarcinoma. *Theranostics*. 2018;8(19):5213-30.
181. Law PT-Y, Qin H, Ching AK-K, Lai KP, Co NN, He M, et al. Deep sequencing of small RNA transcriptome reveals novel non-coding RNAs in hepatocellular carcinoma. *J Hepatol*. 2013;58(6):1165-73.

182. Rizzo F, Rinaldi A, Marchese G, Coviello E, Sellitto A, Cordella A, et al. Specific patterns of PIWI-interacting small noncoding RNA expression in dysplastic liver nodules and hepatocellular carcinoma. *Oncotarget*. 2016;7(34):54650–61.
183. Li Y, Wu X, Gao H, Jin JM, Li AX, Kim YS, et al. Piwi-interacting RNAs (piRNAs) are dysregulated in renal cell carcinoma and associated with tumor metastasis and cancer-specific survival. *Mol Med*. 2015;21(1):381–8.
184. Busch J, Ralla B, Jung M, Wotschofsky Z, Trujillo-Arribas E, Schwabe P, et al. Piwi-interacting RNAs as novel prognostic markers in clear cell renal cell carcinomas. *J Exp Clin Cancer Res*. 2015;34(1):61.
185. Yan H, Wu Q-L, Sun C-Y, Ai L-S, Deng J, Zhang L, et al. piRNA-823 contributes to tumorigenesis by regulating de novo DNA methylation and angiogenesis in multiple myeloma. *Leukemia*. 2015;29(1):196–206.
186. Ai L, Mu S, Sun C, Fan F, Yan H, Qin Y, et al. Myeloid-derived suppressor cells endow stem-like qualities to multiple myeloma cells by inducing piRNA-823 expression and DNMT3B activation. *Mol Cancer*. 2019;18(1):88.
187. Li B, Hong J, Hong M, Wang Y, Yu T, Zang S, et al. piRNA-823 delivered by multiple myeloma-derived extracellular vesicles promoted tumorigenesis through re-educating endothelial cells in the tumor environment. *Oncogene*. 2019;38(26):5227–38.
188. Cordeiro A, Navarro A, Gaya A, Díaz-Beyá M, Gonzalez-Farré B, Castellano JJ, et al.

- PiwiRNA-651 as marker of treatment response and survival in classical Hodgkin lymphoma. *Oncotarget*. 2016;7(29):46002–13.
189. Singh G, Roy J, Rout P, Mallick B. Genome-wide profiling of the PIWI-interacting RNA-mRNA regulatory networks in epithelial ovarian cancers. *PLoS One*. 2018;13(1):e0190485.
190. Qian L, Xie H, Zhang L, Zhao Q, Lü J, Yu Z. Piwi-interacting RNAs: A new class of regulator in human breast cancer. *Front Oncol*. 2021;11:695077.
191. Peng L, Song L, Liu C, Lv X, Li X, Jie J, et al. piR-55490 inhibits the growth of lung carcinoma by suppressing mTOR signaling. *Tumour Biol*. 2016;37(2):2749–56.
192. Cheng J, Deng H, Xiao B, Zhou H, Zhou F, Shen Z, et al. piR-823, a novel non-coding small RNA, demonstrates in vitro and in vivo tumor suppressive activity in human gastric cancer cells. *Cancer Lett*. 2012;315(1):12–7.
193. Liu X, Sun Y, Guo J, Ma H, Li J, Dong B, et al. Expression of hiwi gene in human gastric cancer was associated with proliferation of cancer cells: HIWIGene Expression and Human Gastric Cancer. *Int J Cancer*. 2006;118(8):1922–9.
194. Liu X, Zheng J, Xue Y, Yu H, Gong W, Wang P, et al. PIWIL3/OIP5-AS1/miR-367-3p/CEBPA feedback loop regulates the biological behavior of glioma cells. *Theranostics*. 2018;8(4):1084–105.
195. Jacobs DI, Qin Q, Fu A, Chen Z, Zhou J, Zhu Y. piRNA-8041 is downregulated in

- human glioblastoma and suppresses tumor growth in vitro and in vivo. *Oncotarget*. 2018;9(102):37616–26.
196. Shen S, Yu H, Liu X, Liu Y, Zheng J, Wang P, et al. PIWIL1/piRNA-DQ593109 regulates the permeability of the blood-tumor barrier via the MEG3/miR-330-5p/RUNX3 axis. *Mol Ther Nucleic Acids*. 2018;10:412–25.
197. Leng X, Ma J, Liu Y, Shen S, Yu H, Zheng J, et al. Mechanism of piR-DQ590027/MIR17HG regulating the permeability of glioma conditioned normal BBB. *J Exp Clin Cancer Res*. 2018;37(1):246.
198. Das B, Roy J, Jain N, Mallick B. Tumor suppressive activity of PIWI-interacting RNA in human fibrosarcoma mediated through repression of RRM2. *Mol Carcinog*. 2019;58(3):344–57.
199. Müller S, Raulefs S, Bruns P, Afonso-Grunz F, Plötner A, Thermann R, et al. Next-generation sequencing reveals novel differentially regulated mRNAs, lncRNAs, miRNAs, sdRNAs and a piRNA in pancreatic cancer. *Mol Cancer*. 2015;14(1):94.
200. Statello L, Guo C-J, Chen L-L, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. *Nat Rev Mol Cell Biol*. 2021;22(2):96–118.
201. Bhan A, Mandal SS. LncRNA HOTAIR: A master regulator of chromatin dynamics and cancer. *Biochim Biophys Acta*. 2015;1856(1):151–64.
202. Hajjari M, Salavaty A. HOTAIR: an oncogenic long non-coding RNA in different

- cancers. *Cancer Biol Med.* 2015;12(1):1–9.
203. Davidovich C, Zheng L, Goodrich KJ, Cech TR. Promiscuous RNA binding by Polycomb repressive complex 2. *Nat Struct Mol Biol.* 2013;20(11):1250–7.
204. Li L, Liu B, Wapinski OL, Tsai M-C, Qu K, Zhang J, et al. Targeted disruption of Hotair leads to homeotic transformation and gene derepression. *Cell Rep.* 2013;5(1):3–12.
205. Wu Y, Zhang L, Wang Y, Li H, Ren X, Wei F, et al. Long noncoding RNA HOTAIR involvement in cancer. *Tumour Biol.* 2014;35(10):9531–8.
206. Chen L, Qian X, Wang Z, Zhou X. The HOTAIR lncRNA: A remarkable oncogenic promoter in human cancer metastasis. *Oncol Lett.* 2021;21(4):302.
207. Chiyomaru T, Fukuhara S, Saini S, Majid S, Deng G, Shahryari V, et al. Long non-coding RNA HOTAIR is targeted and regulated by miR-141 in human cancer cells. *J Biol Chem.* 2014;289(18):12550–65.
208. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. *Nature.* 2010;464(7291):1071–6.
209. Zhou Y, Wang Y, Lin M, Wu D, Zhao M. LncRNA HOTAIR promotes proliferation and inhibits apoptosis by sponging miR-214-3p in HPV16 positive cervical cancer cells. *Cancer Cell Int.* 2021;21(1):400.

210. Li Q, Feng Y, Chao X, Shi S, Liang M, Qiao Y, et al. HOTAIR contributes to cell proliferation and metastasis of cervical cancer via targetting miR-23b/MAPK1 axis. *Biosci Rep* [Internet]. 2018;38(1). Available from: <https://portlandpress.com/bioscirep/article-lookup/doi/10.1042/BSR20171563>
211. Liu L-C, Wang Y-L, Lin P-L, Zhang X, Cheng W-C, Liu S-H, et al. Long noncoding RNA HOTAIR promotes invasion of breast cancer cells through chondroitin sulfotransferase CHST15. *Int J Cancer*. 2019;145(9):2478–87.
212. Nakagawa T, Endo H, Yokoyama M, Abe J, Tamai K, Tanaka N, et al. Large noncoding RNA HOTAIR enhances aggressive biological behavior and is associated with short disease-free survival in human non-small cell lung cancer. *Biochem Biophys Res Commun*. 2013;436(2):319–24.
213. Xie H, Ma H, Zhou D. Plasma HULC as a promising novel biomarker for the detection of hepatocellular carcinoma. *Biomed Res Int*. 2013;2013:136106.
214. Zhang X, Gejman R, Mahta A, Zhong Y, Rice KA, Zhou Y, et al. Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression. *Cancer Res*. 2010;70(6):2350–8.
215. McClelland ML, Mesh K, Lorenzana E, Chopra VS, Segal E, Watanabe C, et al. CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. *J Clin Invest*. 2016;126(2):639–52.

216. Teschendorff AE, Lee S-H, Jones A, Fiegl H, Kalwa M, Wagner W, et al. HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer. *Genome Med.* 2015;7(1):108.

© GSJ